Instruction for use: Salmeterol (Salmeterolum)

Chemical name: (±) 4-hydroxy-alpha - [[[6- (4-phenylbutoxy) hexyl] amino] methyl] -1,3-benzenedimethanol (as xinafoate)

Pharmacotherapeutic group:

Beta-adrenergic agonist

The nosological classification (ICD-10)

J42 Chronic bronchitis, unspecified

recurrent bronchitis, Bronchitis asthma, wheeze bronchitis, chronic Bronchitis, Inflammatory airways disease, bronchi disease, Qatar smoker, Cough in inflammatory diseases of the lung and bronchus, Exacerbation of Chronic Bronchitis, Chronic bronchitis, Chronic obstructive pulmonary disease, Chronical bronchitis, Chronic bronchitis smokers, Chronic spastic bronchitis, allergic Bronchitis

J44 Other chronic obstructive pulmonary disease

Allergic bronchitis, Bronchitis asthma, Asthmatic bronchitis, wheeze bronchitis, Bronchitis is an obstructive, bronchi disease, Shortness of sputum in acute and chronic respiratory diseases, Cough in inflammatory diseases of the lung and bronchus, Reversible airflow obstruction, Reversible obstructive airway disease, Obstructive bronchitis disease, Obstructive lung disease, Obstructive bronchitis, Spastic bronchitis, Chronic lung disease, Chronic nonspecific lung diseases, Chronic obstructive pulmonary disease, Chronic obstructive bronchitis, Chronic obstructive airway disease, Chronic obstructive pulmonary disease, Restrictive lung pathology

J45 Asthma

Asthma physical effort, status asthmaticus, Bronchial asthma, Asthma lung flow, Bronchial asthma with obstruction of sputum discharge, Bronchial asthma heavy currents, Bronchial asthma physical effort, hypersecretory asthma, Hormone-dependent form of bronchial asthma, Relief of asthma attacks in bronchial asthma, Non-allergic asthma, nocturnal asthma, Exacerbation of asthma, Asthma attacks, Endogenous forms of asthma, Night asthma, Cough with bronchial asthma

J98.8.0 * Bronchospasm

Bronchospasm in bronchial asthma, Bronchospasm when exposed to an allergen, bronchospastic reactions, bronchospastic status, bronhospastichesky syndrome, Diseases accompanied by bronchospastic syndrome, reversible bronchospasm, spasmodic cough

CAS Cade 89365-50-4

Characteristics

Salmeterol xinafoate - white or off-white powder, easily soluble in methanol, slightly soluble in ethanol, isopropanol and chloroform, sparingly soluble in water. The molecular weight of 603.74.

Pharmacology

Pharmacological effect

bronchodilatory, antiasthmatic.

Selectively excites the beta2-adrenergic receptors. It stimulates intracellular adenylate cyclase, increases the formation of cAMP. It causes relaxation of bronchial smooth muscle and inhibits the release of mediators from mast cells. It promotes long-term (up to 12 h) bronchodilation in patients with reversible airflow obstruction. Regular use of salmeterol provides persistent improvement in the functioning of the lungs, reducing the severity of airway obstruction syndrome and nocturnal asthma attacks. It prevents the release of histamine, leukotrienes and PGD2 from mast cells, has anti-inflammatory activity, reduces the intensity of the primary and secondary bronchial responses to inhaled allergens.

Indication

Reversible airway obstruction: bronchial asthma (prevention of bronchospasm provoked by exercise or nocturnal asthma attacks), chronic obstructive bronchitis.

Contraindications

Hypersensitivity, children's age (up to 4 years).

Restrictions apply

Thyrotoxicosis, arrhythmia, coronary heart disease, uncontrolled hypertension, hypoxia of different genesis, pheochromocytoma, pregnancy, lactation, old age (a high risk of side effects).

Pregnancy and breast-feeding

Category effects on the fetus by FDA - C.

Side effects of Salmeterol

Cardio-vascular system and blood (blood, hemostasis): tachycardia, increased Sad and / or lowering Dad; in predisposed patients - irregular heartbeat (atrial fibrillation, supraventricular tachycardia, extrasystoles).

From the digestive tract: diarrhea, abdominal pain, nausea, vomiting, viral gastroenteritis, irritation of the mucous membranes of the mouth or throat.

From the nervous system and sensory organs: headache, dizziness, tremors, nervousness, excitement, insomnia, change in taste.

From the respiratory system: paradoxical bronchospasm (requires discontinuation), cough.

Other: arthralgia, hypokalemia, allergic reactions; Local reactions: rhinitis, laryngitis.

Interaction

MAO inhibitors and tricyclic depressants increase the risk of side effects from the CCC. Xanthine derivatives, glucocorticoids, and diuretics increases the risk of hypokalemia, especially in patients with severe asthma, as well as hypoxic conditions (required control level of potassium in the blood plasma). Compatible (possible simultaneous inhaled corticosteroid and / or an acid kromoglitsievoy.

Overdose

Symptoms: tachycardia and / or arrhythmia, headache, tremor, hypokalemia and hyperglycemia.

Treatment: a transition to alternative products, the introduction of cardioselective beta-blockers.

Routes of administration

Inhalation.

Precautions

Not available for the relief of bronchospasm. With care prescribe a drug to patients with hyperthyroidism, patients with severe asthma, during hypoxia of any origin.

The therapeutic effect may be reduced when cooling the inhaler.

If the recommended doses are not effective, it needs to increase. It should be understood that regular use of salmeterol most patients typically reduce the need for the additional use of short-sympathomimetics.

We can not allow the aerosol in the eye.